Scarica l'app Stockscreener
1.40
4.76%
-0.07
Dopo l'orario di chiusura:
1.41
0.01
+0.71%
Precedente Chiudi:
$1.47
Aprire:
$1.46
Volume 24 ore:
163.06K
Relative Volume:
0.41
Capitalizzazione di mercato:
$37.22M
Reddito:
$50,000
Utile/perdita netta:
$-45.93M
Rapporto P/E:
-0.7276
EPS:
-1.9241
Flusso di cassa netto:
$-23.62M
1 W Prestazione:
+2.19%
1M Prestazione:
+25.00%
6M Prestazione:
-23.08%
1 anno Prestazione:
-82.28%
Intervallo 1D:
$1.40
$1.46
Intervallo di 1 settimana:
$1.34
$1.5199
Portata 52W:
$1.09
$11.64
Inmune Bio Inc Stock (INMB) Company Profile
Nome
Inmune Bio Inc
Settore
Industria
Telefono
(858) 964-3720
Indirizzo
225 NE MIZNER BLVD, SUITE 640, BOCA RATON, CA
Compare INMB vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
INMB
Inmune Bio Inc
|
1.40 | 39.08M | 50,000 | -45.93M | -23.62M | -1.9241 |
VRTX
Vertex Pharmaceuticals Inc
|
430.14 | 108.36B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
731.77 | 78.05B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
775.03 | 48.74B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
302.11 | 41.16B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
298.16 | 33.17B | 5.36B | 287.73M | 924.18M | 2.5229 |
Inmune Bio Inc Stock (INMB) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-01 | Downgrade | BTIG Research | Buy → Neutral |
| 2025-07-01 | Downgrade | Scotiabank | Sector Outperform → Sector Underperform |
| 2025-01-28 | Iniziato | Rodman & Renshaw | Buy |
| 2024-10-21 | Iniziato | Alliance Global Partners | Buy |
| 2024-09-27 | Iniziato | Raymond James | Outperform |
| 2024-08-22 | Iniziato | Scotiabank | Sector Outperform |
| 2023-06-01 | Iniziato | Robert W. Baird | Outperform |
| 2022-05-24 | Downgrade | B. Riley Securities | Buy → Neutral |
| 2021-07-07 | Reiterato | Maxim Group | Buy |
| 2021-04-21 | Iniziato | B. Riley Securities | Buy |
| 2021-01-22 | Reiterato | Maxim Group | Buy |
| 2020-09-01 | Iniziato | BTIG Research | Buy |
| 2020-07-15 | Reiterato | H.C. Wainwright | Buy |
Mostra tutto
Inmune Bio Inc Borsa (INMB) Ultime notizie
INMB stock rises pre-market – what did the FDA say about its Alzheimer’s trial? - MSN
INmune Bio (INMB) price target increased by 33.33% to 7.14 - MSN
Quant snapshot: J. Jill, AngioDynamics leads strong buys as INmune Bio, Terrestrial Energy lag - MSN
Expanded equity plan and board elections on deck at INmune Bio (NASDAQ: INMB) 2026 meeting - Stock Titan
INMB 260515 1.00P (INMB260515P1000) Stock Options Chain | Quotes & News - Moomoo
What is the sentiment on INmune Bio (INMB) stock today (Institutional Selling) 2026-04-20Strong Buy Rating - Cổng thông tin điện tử tỉnh Lào Cai
INmune Bio Inc. (INMB) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
INMB Unveils Promising Preclinical Data for INB03 at Upcoming AA - GuruFocus
INmune Bio presents preclinical data on INB03 at AACR meeting By Investing.com - Investing.com Australia
Inmune Bio Inc stock (US45764T1060): Why does its innate immune focus matter more now for biotech in - AD HOC NEWS
INmune Bio presents preclinical data on INB03 at AACR meeting - Investing.com
INmune Bio Inc. Announces New Preclinical Data at AACR 2026 Demonstrating INB03 (XPro1595) Overcomes Resistance and Reduces Metastases in HER2-Positive Breast Cancer Models - The Manila Times
Breast cancer models show INmune Bio drug cut brain metastases - Stock Titan
INMune Bio, Inc. (NASDAQ:INMB) Q4 2025 earnings call transcript - MSN
Options Flow: Does INmune Bio Inc have a competitive edge2026 Macro Impact & Real-Time Chart Breakout Alerts - baoquankhu1.vn
Aug Highlights: What is the earnings history of INmune Bio IncBond Market & Community Consensus Stock Picks - baoquankhu1.vn
Lucid Capital Markets upgrades INmune Bio (INMB) - MSN
Analysis Recap: Whats the RSI of INmune Bio Inc stock2026 Trade Ideas & Daily Chart Pattern Signal Reports - baoquankhu1.vn
Inmune Bio Inc stock: What investors need to know about its biotech potential now - AD HOC NEWS
INmune Bio Inc Issues Shareholder Letter Reviewing 2025 Milestones and Outlining 2026 Strategic Initiatives - ADVFN
Can INmune Bio (INMB) Stock Beat the Market | Price at $1.25, Up 3.72%Verified Stock Signals - Xã Châu Thành
Support Test: Whats the RSI of INmune Bio Inc stockWeekly Investment Report & Capital Efficiency Focused Strategies - baoquankhu1.vn
INMB.O PE Ratio & Valuation, Is INMB.O Overvalued - Intellectia AI
INMB Stock Analysis: INmune Bio Inc. Common stock holds $1.21 level after 1.63% daily dip - Cổng thông tin điện tử tỉnh Tây Ninh
INmune Bio, Inc. (NASDAQ:INMB) Q4 2025 Earnings Call Transcript - Insider Monkey
INmune Bio (NASDAQ:INMB) Will Have To Spend Its Cash Wisely - Yahoo Finance
S P Trends: Whats the profit margin of INmune Bio IncWeekly Trade Report & Weekly Stock Performance Updates - baoquankhu1.vn
INmune Bio, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Earnings Call Summary | INmune Bio(INMB.US) Q4 2025 Earnings Conference - Moomoo
Inmune Bio Inc Stock: Recent 2025 Results Highlight Late-Stage Pipeline Progress Amid Cash Runway to - AD HOC NEWS
INmune Bio reports $45.9M loss, plans UK regulatory filing By Investing.com - Investing.com South Africa
INmune Bio Inc (INMB) Q4 2025 Earnings Call Highlights: Strategic Advances Amid Financial Challenges By GuruFocus - Investing.com Canada
INmune Bio Q4 2025 Earnings Call Transcript - MarketBeat
INmune Bio Inc (INMB) Q4 2025 Earnings Call Highlights: Strategi - GuruFocus
INmune Bio Inc reports results for the quarter ended September 30Earnings Summary - TradingView
Earnings call transcript: INmune Bio highlights CORDStrom progress in Q4 2025 - Investing.com Canada
INmune Bio | 10-K: FY2025 Annual Report - Moomoo
INMB: CORDStrom nears regulatory filings as cash runway extends to Q1 2027 after $27.5M raised - TradingView
Pipeline reset at INmune Bio (NASDAQ: INMB) after CORDStrom gains and XPro setback - Stock Titan
Inmune Bio Inc Azioni (INMB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.29%
0.00%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):